Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31245754 | 1.00 | CYP1A2 (0.57) | CYP1A2CYP2C9CYP2C19ESR1ALDH1A1 | |
| SCHEMBL5166111 | 0.88 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19ALDH1A1HPGD | |
| SCHEMBL2432349 | 0.87 | GAA (0.51) | CYP1A2CYP2C9CYP2C19GAAKIF11 | |
| SCHEMBL5958672 | 0.86 | ESR1 (0.54) | CYP1A2CYP2C9CYP2C19ESR1ALDH1A1 | |
| SCHEMBL19462358 | 0.85 | HDAC1 (0.56) | CYP2C19ALDH1A1HPGDGAAKIF11 | |
| SCHEMBL9185909 | 0.84 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL31434967 | 0.84 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL11775650 | 0.84 | GAA (0.49) | CYP1A2CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL5544752 | 0.84 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19ALDH1A1RXFP1 | |
| SCHEMBL15604416 | 0.84 | ESR1 (0.57) | CYP1A2CYP2C9CYP2C19ESR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2024153155-A1 | DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都微芯药业有限公司 | 2024-07-25 | — | — | WO | disclosed |
| EP-4347596-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-11878973-B2 | Bicyclic compounds and their uses | NOVARTIS AG (CH) | 2024-01-23 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2022249060-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
| US-20210395243-A1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7449493-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7145035-B2 | Methods of ortho alkylation | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| CN-1604891-A | Improved methods of ortho alkylation | DU PONT (US) | 2005-04-06 | — | — | CN | disclosed |
| US-20040082793-A1 | Methods of ortho alkylation | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| EP-1368310-A2 | IMPROVED METHODS OF ORTHO ALKYLATION | E. I. du Pont de Nemours and Company (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072540-A2 | IMPROVED METHODS OF ORTHO ALKYLATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878973-B2 | Bicyclic compounds and their uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | CYP1A2 718/4885CYP2C9 270/4885CYP2C19 435/4885 |
| US-20040082793-A1 | Methods of ortho alkylation | CBR1, AOC2, CBR3 | CYP1A2 127/4885CYP2C9 183/4885CYP2C19 470/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | CYP1A2 2621/4885CYP2C9 1834/4885CYP2C19 1010/4885 |
| US-20210395243-A1 | PESTICIDAL COMPOUNDS | NIT2, PNMT, DDT | CYP1A2 112/4885CYP2C9 105/4885CYP2C19 515/4885 |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | CYP1A2 718/4885CYP2C9 270/4885CYP2C19 435/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CYP1A2 284/4885CYP2C9 534/4885CYP2C19 325/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CYP1A2 284/4885CYP2C9 534/4885CYP2C19 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.